Blog

LONDON, UK / ACCESS Newswire / November 14, 2025 / Two pioneering studies published in the journal Animals have explored in depth how dog and cat guardians perceive more sustainable pet food options. Led by Jenny L. Mace, Alexander Bauer, Andrew Knight and Billy Nicholles, the research sheds new light on the potential for alternative proteins and plant-based diets in the companion animal sector.

Study 1 – Dogs: ‘Consumer Acceptance of Sustainable Dog Diets: A Survey of 2,639 Dog Guardians’

In the first study, the team surveyed 2,639 dog guardians worldwide. Around 84% of respondents were currently feeding their dogs either conventional or raw meat-based diets. However, a substantial 43% of this group reported they would nevertheless consider at least one type of more sustainable dog food (such as vegan, vegetarian or cultivated-meat formulations).

Among the alternative options, the most acceptable was cultivated meat-based dog food (chosen by 24% of these respondents), compared to vegetarian (17%) and vegan (13%) dog diets. And when asked what characteristics would be needed for these alternatives to be chosen, the top choices were nutritional soundness (chosen by 85%) followed by good pet health (83%).

Study 2 – Cats: ‘Consumer Acceptance of Sustainable Cat Diets: A Survey of 1,380 Cat Guardians’

The companion study gathered responses from 1,380 cat guardians. In total 89% of these guardians fed their cats conventional or raw meat-based diets. However, just over half – 51% – of this group considered at least one of the more sustainable options to be acceptable.

The most popular alternatives were those based on cultivated meat (chosen by 33% of this group) followed by vegan diets (18%). Similarly to dogs, the most important characteristics alternative diets would need to offer be chosen were good pet health outcomes (chosen by 83%) and nutritional soundness (80%).

Differences among consumers

Both studies found that guardians who themselves reduce or avoid meat were significantly more open to alternative diets for their pets, as were those with higher educational qualifications. Age and regional differences were also apparent, with older consumers, and those from the UK, often less open to alternatives than those in other European nations, North America or Oceania, although differences were often not significant.

What This Means

These twin studies come at a time when the environmental and ethical footprint of conventional pet food production is growing in public consciousness. As noted by study co-author and veterinary professor Andrew Knight: “Recent studies have demonstrated that our dogs and cats collectively consume a substantial proportion of all farmed animals. Pet diets such as those based on plant-based ingredients or cultivated meat could transform the pet food system, lowering adverse impacts for farmed animals and the environment.”

With rapidly increasing populations already numbering hundreds of millions of dogs and cats globally, the shift of even a modest percentage of these pets to lower-impact diets could bring significant benefits.

As co-author Billy Nicholles summarised: “These findings are of value to the rapidly growing pet food alternatives industry, enabling pet food companies to accelerate their growth and acquire new customers through evidence-based, targeted outreach.”

Implications for Industry and Veterinary Practice

For pet food companies, the message is clear: launching sustainable diet lines is not merely a matter of production innovation, but also of trust-building. Clear information about nutritional soundness and health outcomes feature heavily in guardian willingness to adopt new products.

For veterinary practitioners and animal welfare organisations, these findings underscore the importance of informed communication. If guardians are open to alternatives but uncertain about their pet’s health outcomes, then evidence-based guidance becomes a key enabling factor.

Further information
Andrew Knight
Veterinary Professor of Animal Welfare
Andrew.Knight@murdoch.edu.au

SOURCE: Sustainable Pet Food Foundation

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 14, 2025 / Every region that grows eventually confronts a question it cannot ignore: who can prove what actually happened. Europe hit that point the moment regulators began tying economic incentives to measurable sustainability. Suddenly, recycling claims were not enough. Companies needed evidence. Industries needed confidence. Governments needed traceable performance.

Spain answered that call first. In Valladolid, a new model for industrial growth is taking shape through a collaboration between SMX (NASDAQ:SMX) and CARTIF,one of Europe’s most influential applied research hubs. Their work is turning the idea of a circular economy into something concrete and accountable, functioning as both a scientific system and an economic engine.

The Castilla y León region has long been an industrial heavyweight, with an annual output of billions. Now it is positioning itself as something deeper. Growth will not hinge on volume. It will hinge on verifiable value. That shift begins with the way materials are traced, authenticated, and reintegrated into production cycles.

Where Spain’s Industrial Base Meets Molecular Truth

SMX provides the foundation. Its molecular tracing system allows materials to carry their own identity, a physical signature that stays embedded throughout manufacturing, reuse, and recycling. It functions like a memory. Once applied, the marker bonds at the molecular level, creating a digital passport that travels with the material at every stage.

This gives companies something that never existed at scale in Europe. A way to confirm the origin. A way to audit real-world movement. A way to verify return into the value chain with scientific certainty.

CARTIF then turns that capability into performance. With SMX embedded across its pilot plants and applied research programs, Spain gains a real-time measurement loop that links innovation to documented results. Data that once took years to gather through surveys and audits now appears instantly through verified material activity. Companies can qualify for grants faster. They can meet compliance targets faster. They can validate R&D faster. Evidence becomes a growth strategy.

Innovation That Speeds Up the Economy Instead of Slowing It

The pace of verification is the real breakthrough here. For decades, businesses treated sustainability as something that consumed time and margin. Now the opposite is true. Once a material carries a verifiable passport, its journey becomes a bankable metric. Lenders can underwrite it. Regulators can trust it. Markets can reward it.

SMX and CARTIF effectively connect environmental behavior to financial upside, turning transparency into a competitive lever instead of an operational burden. A circular economy with credible measurement does not drain resources. It compounds them.

Spain stands on the shoulders of global proof. SMX demonstrated this model at the national scale in Singapore through its work with A*STAR. That initiative tracked waste streams, verified recycled content, and established a tradable digital framework for circular materials. The success of that effort created a blueprint that now connects Asia and Europe through a shared layer of traceable, measurable sustainability.

Proof That Scales Beyond Borders

The system demonstrated in Singapore and Valladolid is not local. It is universal. A molecular signature embedded in Spanish packaging can function the same way inside an Italian food processor, a German automotive plant, or a French construction project. Verification travels without friction.

Every new material added to the network strengthens its resonance. The result is a distributed web of authenticated activity that gradually reshapes how Europe measures industrial performance.

CARTIF plays a central role in this expansion. Its sustainability programs span packaging, renewables, mobility systems, construction materials, and critical resources. With SMX feeding verified data into those programs, Spain becomes a proving environment that links research, industry, and public policy into one loop of measurable progress.

Deputy General Manager Sergio Sanz has been clear. The technology delivers exactly what companies need to prove their claims, refine their processes, and demonstrate circular performance with scientific precision. That alignment is what transforms proof into actionable value.

Europe’s New Industrial Playbook Begins in Spain

Spain is not just deploying technology. It is defining a new framework for European industry. One where innovation is tied to measurement, and measurement is tied to growth. Academics, startups, manufacturers, and local governments now operate with a shared layer of data they can all trust.

This creates a coordinated marketplace of evidence. It removes uncertainty. It creates incentives for verification instead of incentives for vague declarations.

Circularity only becomes meaningful when it is measurable. It is not enough to say a product was recycled or reused. The world needs confirmation that the cycle occurred. SMX supplies the identity. CARTIF supplies the scale. Together, they convert the circular economy from promise to proof and from proof to economic performance.

This moment marks the beginning of Europe’s next industrial chapter. A shift toward regenerative growth powered by verifiable action. Each traced material adds measurable worth. Each verified transaction acts as an economic weight. Each validated process tightens the loop of material efficiency across the continent.

Circularity in Europe is no longer just a concept. Thanks to the partnership between SMX and CARTIF, it is becoming functional, profitable, and real.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This editorial contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward looking statements reflect expectations and assumptions regarding future events involving SMX (NASDAQ: SMX), its collaborative initiatives with CARTIF, its molecular tracing technologies, and the development and expansion of verified circularity programs in Spain, the European Union, and other global regions. Forward looking statements are not historical facts. They are based on current beliefs, estimates, and assumptions that are subject to risks, uncertainties, and variables that are difficult to predict.

Forward looking statements in this editorial include, without limitation, expectations concerning the continued integration and performance of SMX’s molecular physical-to-digital technology; anticipated commercial deployment across industrial sectors in Castilla y León and Europe; the potential scalability of SMX’s material-level verification systems into research programs, supply chains, and pilot plants operated by CARTIF; and the projected ability of these systems to enhance grant qualification, regulatory compliance, material recovery, and sustainability-linked financing. These statements also include expectations regarding advancements in Spain’s circular economy infrastructure; the potential for SMX and CARTIF to create new economic efficiencies through verified material flows; anticipated alignment with European Union regulatory frameworks, including the Digital Product Passport, sustainability reporting standards, and ESG-linked financing mechanisms; and the potential for global replication of systems demonstrated in Singapore and Europe.

Additional forward looking statements relate to broader market and industry conditions, including the belief that verifiable traceability may increase brand value, reduce compliance costs, accelerate adoption of circular supply chains, and unlock new revenue opportunities tied to authenticated material movements. Assumptions concerning future demand for verifiable recycled content, the maturation of circular economies across global markets, and the potential for SMX technologies to enable transparent material ecosystems also fall within the scope of these statements.

These forward looking statements are subject to numerous risks and uncertainties that could cause actual outcomes to differ materially from those expressed or implied. Factors that may impact results include, but are not limited to: changes in European Union regulatory requirements; shifts in consumer, corporate, or governmental sustainability priorities; macroeconomic conditions; geopolitical developments; supply chain disruptions; competitive technological advancements; scientific or technical challenges in large-scale deployment of molecular markers; operational risks in pilot or commercial settings; and other factors described in SMX’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect subsequent events, changes in circumstances, or new information, except as required by applicable law.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

RESEARCH TRIANGLE PARK, NC / ACCESS Newswire / November 13, 2025 / Cyberlux Corporation (OTC:CYBL), a leading defense technology innovator, today announced the next phase of the Company’s Defense Industry UAS Strategy, redefining how small Group 1 unmanned aircraft systems (UAS) are developed, produced, and deployed in modern conflict environments.

The next phase of strategy establishes Cyberlux as a driving force in attritable, high-impact UAS systems, designed to deliver mass, modularity, and mission adaptability at the lowest possible cost. By offering a FPV (First Person View) UAS as “ammunition, not aircraft,” Cyberlux aims to become the “Kalashnikov of drones” – delivering scalable, expendable systems to defense customers globally.

Revolutionizing Defense Through Attritable Economics

Cyberlux’s new models focus on delivering near front line production of UAV airframes using proven technology applied in new ways. These include unique methods of manufacture, 3D-printed systems, and traditional methods common to our expertise. The focus is on cost efficiency and scalability, with a variety of different offerings dependent on our partner’s requirements. NDAA-compliant for US Military sales as well as readably available commercial off-the-shelf (COTS) components for Foreign Military Sales (FMS). This multi-faceted approach enables defense customers and partner nations to choose how they wish to deploy drones rapidly, consistently, with production at or near the front lines.

Each Cyberlux-designed system can be licensed for local manufacture, providing partners with cost-effective production with vastly improved logistical considerations, while ensuring a scalable, forward-deployed supply chain for critical missions.

A Modular Family of FPV Systems

At the core of the strategy is a Family of Systems (FoS), each platform tailored to specific mission profiles, payloads, and operational environments:

• Spider (small) – Lightweight, low-cost rucksack-portable attritable strike-capable one way or single use FPV system delivering 1.5 lb. payloads.

• Huntsman (medium) – Tactical, low-cost FPV platform capable of attritable one-way strike and precision payload-delivery mission profiles of up to 4 lbs, bridging the gap between small expendables and fixed-wing systems.

• Tasmanian (large) – Heavy-lift, affordable, dual-use FPV capable of ISR and munitions delivery, with multiple gimbal options and 10 lbs payload capacity.

• Weaver (trainer) – Compact, affordable FPV training drone developed to establish Cyberlux as the premier provider of FPV operator training, addressing the DoD’s growing need for skilled UAS pilots, which can also be used for tactical reconnaissance by all troops.

This modular, scalable approach ensures each platform can be customized rapidly for mission-specific requirements – from electronic warfare (EW) and intelligence surveillance recognizance (ISR) payloads to kinetic payloads that builds on current partnerships such as the Optical Knowledge Systems, Inc. OMNISCIENCE™ autonomy suite artificial intelligence / machine learning (AI/ML) Integration Agreement and the Strategic Collaboration Agreement with Argus Industrial, LLC on kinetic payloads.

Training the Next Generation of UAS Operators

Recognizing that FPV piloting is a highly perishable skillset, the Cyberlux UAS strategy includes a dedicated training and simulation ecosystem. Through its Train-the-Trainer (T3) program, Cyberlux will deliver both hardware and curriculum solutions, empowering U.S. and allied forces to rapidly scale FPV proficiency across their ranks.

Positioned for Growth and Global Defense Leadership

“Cyberlux is leading the transformation of defense industry UAS from boutique systems into mass-production, mass-deployable, attritable munitions. Our objective is to make advanced UAS capability accessible and scalable for defense and allied customers fast to build, affordable to deploy, and lethal in effect,” said Mark Schmidt, CEO of Cyberlux Corporation. “By combining modular design, manufacturing licenses, and a comprehensive training ecosystem, we enable partners to field affordable, mission-effective systems while maintaining strict compliance with export controls and end-use safeguards.

Cyberlux is among only a handful of defense companies to have successfully delivered over 2,000 unmanned aerial systems under U.S. Department of Defense contracts, a milestone that underscores the company’s proven ability to move from concept to combat capability at scale. As a result, Cyberlux is positioned at the forefront of the next generation of battlefield autonomy, blending agility, affordability, and adaptability to meet the evolving demands of modern warfare.

SAFE HARBOR STATEMENT

This Press Release may contain forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s OTC/SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

For media inquiries, please contact:
Email: ir_cybl@Cyberlux.com | Phone: (984) 363-6894

SOURCE: Cyberlux Corporation

View the original press release on ACCESS Newswire

• Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy Network’) and telehealth partners mitigate patient muscle loss in the GLP-1 drug market, estimated to grow to $150 billion by 2030

• Company to offer first SARS-CoV-2 related natural antiviral combo for Long COVID with addition of 3CL protease inhibitor supplement Tollovid^® to Galectovid 1 & 3 inhibitor Medical Food Galectovid^® distribution agreement to Pharmacy Network & physicians

TAMPA, FLORIDA / ACCESS Newswire / November 14, 2025 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a leader in the integration of physical and technology healthcare infrastructure for prescription drugs, today announced that it has expanded its agreement with Tollo Health to offer the first GLP-1 companion muscle loss medical food to its 6,500+ independent pharmacy network (‘Pharmacy Network’) and physicians. The product is a branded version of a proprietary formulation that has been widely studied in metabolic dysfunction, with patients presenting diabetes type 2, heart failure, and COPD. Wellgistics will be selling the medical food as an adjunct to GLP-1 therapies to help mitigate muscle loss during weight loss while on therapy and to mitigate weight after discontinuation.

“With the GLP-1 muscle loss market sitting at $53 billion annually according to Grandview Research and expected to reach $156 billion by 2030, driven by increase in numbers of patients and availability of oral formulation, the key side effect described by patients is outsized muscle loss,” said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. “By bringing to market a medical food alternative with significant clinical data in mitigating sarcopenia, even increasing muscle mass and strength, we are first to market with a data-driven, proprietary formulation that can potentially help patients more safely take this class of medication. We believe there is significant interest in a product to preserve muscle mass and increase strength as an pharmacy and/or physician recommend adjunct to prescription GLP-1 medications.”

Concurrent with this announcement, the Company announced that it has expanded its antiviral offering by adding 3CL protease inhibitor product Tollovid^® to its already marketed galectin 1 & 3 inhibitor medical food Galectovid^™ primarily targeting patients with Long COVID. Tollovid combined with Galectovid represent the first natural antiviral combination available in the market targeting SARS-CoV-2 specific replication and immune function mechanisms.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

For more information, visit www.wellgisticshealth.com.

About Tollo Health, LLC

Tollo Health, LLC is a medical foods and precision neutraceutical company seeking to bring to market proprietary formulations for the dietary management of GLP-1 treatment-related side effects and chronic viral conditions, include Long COVID. Tollo intends to bring to market a full suite of products that provide patients with prescription medication-enabling benefits in areas with approved drugs and functional relief in conditions for which there are no approved drugs, but mechanistic understanding of the disease is improving. By using tailored natural product formulation that deliver the cGMP-manufactured ingredients with the right formulation at the right dose, Tollo aims to fill a key gap in the delivery of prescription drugs that have side effects and chronic conditions for which there are no approved treatments. For more information, please visit Tollo’s website at www.tollohealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

Investor Relations Contact

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received an unfavorable decision from the U.S. Food & Drug Administration (“FDA”) in response to its supervisory appeal of the not-approvable letter it received on August 19, 2025 in response to its Premarket Approval (PMA) application for VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI). The supervisory appeal upheld the review staff decision in the not-approvable letter that the VenoValve did not meet the standard of reasonable assurance of safety and effectiveness.

“Although the appeal decision was not the result we are looking for, it did provide valuable insight into the criteria that would be necessary for approval of enVVe, our next generation transcatheter based replacement venous valve,” said Robert Berman, enVVeno Medical’s Chief Executive Officer. “enVVe should have a different safety profile than an open surgical device and is ready for human testing. Assuming that we can reach alignment with the Agency on achieveble endpoints for enVVe, it makes sense to turn our attention and devote our resources to enVVe. We will continue to interact with the FDA on enVVe and will provide periodic updates on our progress.”

The Company reported $31.5 million in cash and investments at the end of the third quarter. With its quarterly cash burn of $4 to $5 million a quarter, the Company has sufficient cash to fund operations into 2027.

Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that there are approximately 2.5 million to 3.5 million patients with severe deep venous CV I in the U.S. including approximately 1.5 million patients that develop venous leg ulcers (C6 patients). The average patient seeking treatment of a venous ulcer spends as much as $30,000 a year on wound care, and the total direct medical costs from venous ulcer sufferers in the U.S. has been estimated to exceed $20 billion a year.

About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is developing surgical and non-surgical replacement venous valves for the treatment of deep venous CVI.

Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire